Follows pregnant women taking ozanimod and their babies' health
Observes outcomes in pregnant women with multiple sclerosis who take ozanimod.
Plain-language title generated from the registry record
Registry title: A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Key facts
- Where
- Herne, GermanySee the site
Where in Germany
- Marienhospital Herne, Klinikum Der Ruhr-Universitaet BochumHerne, GermanyTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Bristol-Myers Squibb
- Trial code
- NCT05170126
- Record updated
- 20 November 2025
- Original description
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.Read full original descriptionShow less
ZEPOSIA® (Ozanimod) Pregnancy Registry: A Prospective, Observational Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
Inclusion: Diagnosis of Multiple sclerosis (MS); Currently or recently pregnant; Reside in the United States, Canada or Germany.
Exclusion: Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester; Other protocol-defined inclusion/exclusion criteria apply.